Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | DZD8586 |
Synonyms | |
Therapy Description |
DZD8586 is a non-covalent inhibitor of BTK and LYN that is blood-brain barrier-penetrant, which potentially induces tumor cell death and decreases tumor growth (Blood (2023) 142 (Supplement 1): 2822). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
DZD8586 | DZD-8586|DZD 8586 | BTK inhibitor 37 LYN Inhibitor 4 | DZD8586 is a non-covalent inhibitor of BTK and LYN that is blood-brain barrier-penetrant, which potentially induces tumor cell death and decreases tumor growth (Blood (2023) 142 (Supplement 1): 2822). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05824585 | Phase I | DZD8586 | DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | Recruiting | USA | AUS | 0 |